Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 22, 2021 | Post-IPO Equity | $45M | — | — | — | Detail |
Apr 16, 2021 | Post-IPO Equity | $30M | — | — | — | Detail |
Jun 12, 2019 | Post-IPO Equity | $80M | 1 | Ginkgo Bioworks | — | Detail |
Jan 23, 2018 | Post-IPO Equity | $50.01M | — | — | — | Detail |
Aug 28, 2017 | IPO | — | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Ginkgo Bioworks | Yes | Post-IPO Equity |
Bill & Melinda Gates Foundation | Yes | Series A |
Aju IB Investment | — | Series C |
Ally Bridge Group | — | Series C |
Arctic Aurora LifeScience | — | Series C |
Atlas Venture | — | Series C |
CLI Ventures | — | Series C |
Daphne Teo | — | Series C |
Deepfield | — | Series C |
New Enterprise Associates | — | Series C |